One of these agents, rociletinib (CO-1686) showed objective response rates of 59% in patients with T790M mutation positive EGFR mutant NSCLC who had progressed on an EGFR inhibitor in a phase I/II trial. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.